Vergoeding 2016-2020 voor ATC-subgroep C09CA : Angiotensine-ii-antagonisten
- Raming voor de totale Zvw-populatie
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| C09CA01 Losartan (Cozaar ®) | 2.367.000 | 2.564.900 | 3.059.000 | 5.492.000 | 5.652.200 |
| C09CA02 Eprosartan (Teveten ®) | 408.410 | 378.180 | 363.030 | 113.320 | 46.900 |
| C09CA03 Valsartan (Diovan ®) | 3.109.200 | 3.226.000 | 3.565.400 | 2.696.100 | 2.509.300 |
| C09CA04 Irbesartan (Aprovel ®) | 2.985.900 | 2.529.500 | 2.643.100 | 4.279.300 | 4.178.600 |
| C09CA06 Candesartan (Atacand ®) | 1.109.000 | 1.086.200 | 1.210.000 | 1.776.500 | 1.983.800 |
| C09CA07 Telmisartan (Micardis ®) | 898.830 | 798.050 | 776.090 | 1.285.300 | 1.442.100 |
| C09CA08 Olmesartan (Olmetec ®) | 2.609.700 | 1.849.000 | 693.080 | 582.060 | 822.790 |
| Totaal | 13.488.040 | 12.431.830 | 12.309.700 | 16.224.580 | 16.635.690 |